A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 37, Issue 2, 2014, Pages 188-193

  Chaudhary, Uzair B ^a   Verma, Nitin ^b   Keane, Thomas ^c   Gudena, Vinay ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAISER PERMANENTE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Bladder cancer; Chemotherapy; Non platinum

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; DEXAMETHASONE; ERYTHROPOIETIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; SEROTONIN 3 ANTAGONIST; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL EVALUATION; COLITIS; CONFIDENCE INTERVAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; VOMITING; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; NAUSEA; PATHOLOGY; URINARY BLADDER NEOPLASMS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84900516121     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318271b306     Document Type: Article

References (16)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997;15:2564-2569.
3. Kaufman D, Raghavan D, Carducci M, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000;18:1921-1927.
4. Moore MJ, Winquist EW, Murray N, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1999;17:2876-2881.
5. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068-3077.
6. Carles J, Esteban E, Climent M, et al. Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Ann Oncol. 2007;18:1359-1362.
7. Alberts SR, Erlichman C, Sloan J, et al. Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks. Ann Oncol. 2001;12:627-631.
8. Rocha Lima CM, Leong SS, Sherman CA, et al. Irinotecan and gemcitabine in patients with solid tumors: phase I trial. Oncology (Williston Park). 2002;16(suppl 5):19-24.
9. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17: 3173-3181.
10. Yagoda A. Progress in treatment of advanced urothelial tract tumors. J Clin Oncol. 1985;3:1448-1450.
11. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990;8: 1050-1055.
12. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10:1066-1073.
13. Dreicer R, Manola J, Roth BJ, et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer. 2004;100:1639-1645.
14. Meluch AA, Greco FA, Burris HA III, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol. 2001;19: 3018-3024.
15. Gitlitz BJ, Baker C, Chapman Y, et al. A phase II study of Gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer. 2003;98:1863-1869.
16. Turkolmez K, Bedük Y, Baltaci S, et al. Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy. Eur Urol. 2003;44:682-686.